Celldex Therapeutics (CLDX) Change in Receivables (2010 - 2026)

Celldex Therapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 590.38% year-over-year to -$1.8 million in Q1 2026; TTM through Mar 2026 was -$834000.0, a 48.1% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 168.21% from the prior year.
• Change in Receivables fell to -$1.8 million in Q1 2026 per CLDX's latest filing, from $1.9 million in the prior quarter.
• Across five years, Change in Receivables topped out at $2.4 million in Q4 2023 and bottomed at -$1.8 million in Q1 2026.
• The 5-year median for Change in Receivables is $57000.0 (2022), against an average of $3625.0.
• Biggest YoY gain for Change in Receivables was 1403.8% in 2023; the steepest drop was 719.18% in 2023.
• Year by year, Change in Receivables stood at $158000.0 in 2022, then jumped by 1403.8% to $2.4 million in 2023, then slumped by 106.4% to -$152000.0 in 2024, then jumped by 1366.45% to $1.9 million in 2025, then slumped by 192.73% to -$1.8 million in 2026.
• Per Business Quant, the three latest CLDX Change in Receivables figures stand at -$1.8 million (Q1 2026), $1.9 million (Q4 2025), and -$974000.0 (Q2 2025).